GlySens, a biomedical technology company, is a privately owned corporation developing a long term internal continuous glucose monitor in order to effectively manage and observe glucose levels in real time. The GlySens ICGM system is the world's first surgically implanted continuous glucose monitoring system to demonstrate an 18-month performance in a preclinical setting. GlySens Incorporated was founded in 1998 by David A. Gough and Joseph Lucisano, a bioengineering graduate at the University of California, San Diego. The implanted continuous glucose monitoring system uses an internal sensor equipped with electrochemical detectors to measure glucose readings via a chemical reaction between enzymes and oxygen.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:name |
|
foaf:homepage | |
name |
|
location | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
founder |
|
homepage | |
industry |
|
location |
|
num employees |
|
owner |
|
products |
|
revenue |
|
type | |
has abstract |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
founding year |
|
number of employees | |
revenue ($) |
|
industry | |
type | |
foaf:isPrimaryTopicOf | |
is foaf:primaryTopic of |